Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 1, 2012, Pages 34-43

  Fogari, Roberto ^a   Mugellini, Amedeo ^a   Zoppi, Annalisa ^a   Preti, Paola ^a   Destro, Maurizio ^a   Lazzari, Pierangelo ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

amlodipine; atrial fibrillation; hypertension; ramipril; telmisartan

Indexed keywords

AMLODIPINE; CARBOXY TERMINAL TELOPEPTIDE; PROCOLLAGEN; RAMIPRIL; TELMISARTAN; TROPONIN I;

AGED; ANKLE EDEMA; ARTICLE; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DISPERSION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EDEMA; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NAUSEA; OUTPATIENT; P WAVE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE;

AGED; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BENZOATES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; PROSPECTIVE STUDIES; RAMIPRIL; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84856956291     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410395018     Document Type: Article

References (62)

1. Kannel WB, Wolf PA, Benjamin EJ, Levy D.. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998 ; 82 (8A). 2N - 9N (Pubitemid 28507114)
2. Vidaillet H, Granada JF, Chyoi PH, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002 ; 113 (5). 365-370 (Pubitemid 35223607)
3. Umetani K, Kodama Y, Nakamura T, et al. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circ J. 2007 ; 71 (2). 252-255 (Pubitemid 46182700)
4. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation. The Niigata Preventive Medicine Study. Circulation. 2008 ; 117 (10). 1255-1260 (Pubitemid 351365676)
5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel,ATP III). JAMA. 2001 ; 285 (19). 2486-2497
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation. 2005 ; 112 (17). 2735-2752 (Pubitemid 41532612)
7. Mohaved MR, Hashemzadeh M, Jamal MM.. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005 ; 105 (3). 315-318 (Pubitemid 41605083)
8. Dublin S, French B, Glazer NL, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Int Med. 2006 ; 166 (21). 2322-2328 (Pubitemid 44833356)
9. Engelmann MDH, Svendsen JH.. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005 ; 26 (20). 2083-2092 (Pubitemid 41408600)
10. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA.. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol. 2007 ; 115 (2). 135-143 (Pubitemid 46136515)
11. Li D, Fareh S, Leung TK, Nattel S.. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999 ; 100 (1). 87-95 (Pubitemid 29297945)
12. Nattel S, Shiroshita-Takeshita A, Cardin S, Pelletier P.. Mechanisms of atrial remodelling and clinical relevance. Curr Opin Cardiol. 2005 ; 20 (1). 21-25 (Pubitemid 40030306)
13. Bosch RF, Zeng X, Grammer JB, Propovic K, Mewis C, Kuhlkamp V.. Ionic mechanisms of electrical remodelling in human atrial fibrillation. Cardiovasc Res. 1999 ; 44 (1). 121-131 (Pubitemid 29431690)
14. Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004 ; 90 (4). 400-405 (Pubitemid 38406914)
15. Serra JL, Bendersky M.. Atrial fibrillation and the renin-angiotensin system. Ther Adv Cardiovasc Dis. 2008 ; 2 (3). 215-223
16. Mc Ewan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ.. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation. 1998 ; 98 (24). 2765-2773 (Pubitemid 28564014)
17. Yu H, Gao J, Wang H, et al. Effects of the renin-angiotensin system on the current I (to) in epicardial and endocardial ventricular myocytes from the canine heart. Circ Res. 2000 ; 86 (10). 1062-1068 (Pubitemid 30367865)
18. Goette A, Arndt M, Rocken C, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation. 2000 ; 101 (23). 2678-2681
19. Tsai CT, Lai LP, Lin JL, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation. 2004 ; 109 (13). 1640-1646
20. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001 ; 104 (21). 2608-2614 (Pubitemid 33104801)
21. Healey JS, Baranchuck A, Crystal E, Garfinkle M, Yusuf S, Connolly SJ.. Prevention of atrial fibrillation with angiotensin converting enzyme inhibitors and angiotensin receptor blockers:a meta-analysis. J Am Coll Cardiol. 2005 ; 45 (11). 1832-1839 (Pubitemid 40789940)
22. Kishlay A, Mooses AN, Hee TT, Mohiuddin SM.. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006 ; 152 (2). 217-222 (Pubitemid 44093401)
23. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with lon lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002 ; 106 (3). 331-336 (Pubitemid 34778957)
24. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003 ; 24 (23). 2090-2098
25. Anne W, Willems R, Van der Merwe N, Van de Werf F, Ector H, Heidbuchel H.. Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and diuretics. Heart. 2004 ; 90 (9). 1025-1030 (Pubitemid 39127918)
26. Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs amiodarone plus losartan vs amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006 ; 27 (15). 1841-1846 (Pubitemid 44297391)
27. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006 ; 47 (1). 46-50 (Pubitemid 44378223)
28. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009 ; 360 (16). 1606-1617
29. Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 2008 ; 21 (9). 1034-1039
30. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 (15). 1547-1559
31. Dilaveris PE, Gialafos EJ, Chrissos D, et al. Detection of hypertensive patients at risk for paroxysmal atrial fibrillation during sinus rhythm by computer-assisted P-wave analysis. J Hypertens. 1999 ; 17 (10). 1463-1470 (Pubitemid 29509493)
32. Dilaveris PE, Gialafos EJ.. P-wave dispersion:a novel predictor of paroxysmal atrial fibrillation. Ann Noninvas Electrocardiol. 2001 ; 6 (2). 159-165 (Pubitemid 32423403)
33. Diez J, Laviades C, Mayor G, Gil MU, Monreal I.. Increased serum concentrations of procollagen peptides in essential hypertension relation to cardiac alterations. Circulation. 1995 ; 91 (5). 1450-1456
34. Lopez B, Gonzales A, Varo N, Laviades C, Querejeta R, Diez J.. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension. 2001 ; 38 (5). 1222-1226 (Pubitemid 34252835)
35. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L.. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telo peptide of type I collagen: a new serum marker of collagen degradation. Clin Chem. 1993 ; 39 (4). 635-640 (Pubitemid 23118314)
36. Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998 ; 98 (6). 535-540 (Pubitemid 28371251)
37. Meikko J, Niemi S, Risteli J.. Radioimmunoassay of the carboxyterminal pro peptide of human type I procollagen. Clin Chem. 1990 ; 36 (7). 1328-1332
38. Fesmire FM, Fesmire CE.. Improved identification of acute coronary syndrome with second generation cardiac troponin I assay. J Emerg Med. 2002 ; 22 (2). 147-152
39. Zellweger MJ, Schaer BA, Cron TA, Pfistere M, Osswald S.. Elevated troponin levels in the absence of coronary artery disease after supraventricular tachycardia. Swiss Med Wkly. 2003 ; 133 (31-32). 439-441 (Pubitemid 37247851)
40. Kanjwal K, Imran N, Grubb B, Kanjwal Y.. Troponin elevation in patients with various tachycardias and normal epicardial coronaries. Indian Pacing Electrophysiol J. 2008 ; 8 (3). 172-174
41. Patanè S, Marte F, Di Bella G.. Abnormal troponin I levels after supraventricular tachicardia. Int J Cardiol. 2009 ; 132 (2). e57 - e59
42. Aksnes TA, Flaa A, Strand A, Kjeldsen SE.. Prevention of atrial fibrillation in hypertension. Curr Hypertens Rep. 2000 ; 10 (3). 175-181
43. Soran H, Ziglam H, Al-Najjar M, Younis N.. The role of the renin angiotensin system blocking in the management of atrial fibrillation. Acta Cardiol. 2008 ; 63 (4). 457-467
44. Anis RR.. Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation. Exp Clin Cardiol. 2009 ; 14 (1). e1 - e7
45. Caballero R, Delpon E, Valenzuela C, Longobardo M, Tamargo J.. Losartan and its metabolita E3174 modify cardiac delayed rectifier K+ currents. Circulation. 2002 ; 101 (10). 1199-1205 (Pubitemid 30146624)
46. Delpon E, Caballero R, Gomez R, Nunez L, Tamargo J.. Angiotensin II, Angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends Pharmacol Sci. 2005 ; 26 (3). 155-161 (Pubitemid 40313595)
47. Li Y, Li W, Xue J, Han W, Yang S, Gu H.. Effects of losartan on acute atrial electrical remodeling. Chin Med J. 2004 ; 117 (5). 643-646 (Pubitemid 38735814)
48. Ciulla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of randomized trial. Circulation. 2004 ; 110 (5). 552-557 (Pubitemid 39031172)
49. Boldt A, Scholl A, Garbade J, et al. Ace-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol. 2006 ; 101 (3). 261-267
50. Shi Y, Li D, Tardif JC, Nattel S.. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res. 2002 ; 54 (2). 456-461 (Pubitemid 34327924)
51. Gerdtz E, Oikarinen L, Palmieri V, et al. Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for End-point reduction in hypertension (LIFE) study. Hypertension. 2002 ; 39 (3). 739-743 (Pubitemid 34252867)
52. Tu DN, Liao YH, Zou AR, et al. Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels espressed on Xenopus laevis oocytes. Acta Pharmacol Sin. 2008 ; 29 (8). 913-922
53. Celik T, Iyisoy A, Kursaklioglu H, et al. The comparative effectsof telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. Clin Cardiol. 2005 ; 28 (6). 298-302 (Pubitemid 40803516)
54. Weber KT.. Fibrosis and hypertensive heart disease. Curr Opin Cardiol. 2000 ; 15 (4). 264-272 (Pubitemid 30496722)
55. Kallergis EM, Manios EG, Kanoupakis EM, et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation. J Am Coll Cardiol. 2008 ; 52 (3). 211-215
56. Yamagishi S, Takeuchi M.. Telmisartan is a promising cardiometabolic sartan, due to its unique PPAR-gamma inducing property. Med Hypotheses. 2005 ; 64 (3). 476-478 (Pubitemid 40023005)
57. Takano H, Hasegawa H, Zou Y, Komuro I.. Pleiotropic actions of PPAR gamma activators thiazolinediones in cardiovascular disease. Curr Pharm Des. 2004 ; 10 (22). 2779-2786 (Pubitemid 39137176)
58. Shimano M, Tsuji Y, Inden Y, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm. 2008 ; 5 (3). 451-459
59. Yamagishi SI, Matsui T, Nakamura K.. Possible molecular mechanisms by which angiotensin type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients. Horm Metab Res. 2008 ; 40 (9). 640-644
60. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma modulating activity. Hypertension. 2004 ; 43 (5). 993-1002 (Pubitemid 38579904)
61. Effect of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008 ; 372 (9644). 1174-1183
62. Kakuta H, Sudoh K, Sasamata M, Yamagishi S.. Telmisartan has the strongest binding affinity to angiotensin type I receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005 ; 25 (1). 41-46 (Pubitemid 40571342)